Latest RNAi Stories
Study finds that the Solstice-licensed technology allows efficient delivery of RNAi prodrugs SAN DIEGO, Nov.
According to new report from BCC Research, the global market RNA interference (RNAi) drug delivery technologies is expected to grow to nearly $38.8 billion by 2018, with a five-year compound annual
DUBLIN, April 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/5wxkx8/global_rna ) has announced the addition of the "Global RNA
WESTBOROUGH, Mass., March 14, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies
ReportsnReports.com adds “Global RNA Interference (RNAi) Therapy Market Outlook 2018” reports to its vast collection of research databases. Dallas, Texas
WESTBOROUGH, Mass., March 4, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies
WESTBOROUGH, Mass., Feb.
WESTBOROUGH, Mass., Jan.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.